UPDATE 1-Amgen expects denosumab data in February

(Adds additional expected data dates)

NEW YORK, Sept 28 (Reuters) - Amgen Inc (AMGN.O) said on Friday it expects to receive head-to-head data in February on its most important drug in development, denosumab, versus alendronate, which is sold by Merck & Co (MRK.N) as Fosamax, for treating post-menopausal osteoporosis.

Amgen, the world's largest biotechnical company, also said it expects to have Phase 3 post-menopausal osteoporosis fracture data in the second half of 2008, and is on target to review the entire post-menopausal osteoporosis data set in the second half of 2008.

The update on the development pipeline was given by Amgen's executive vice president of Research and Development, at UBS Global Life Sciences Conference on Sept. 27. (Reporting by Ilaina Jonas)